Compare Nasdaq100 ETF (QQQ) vs Stryker Corporation (SYK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nasdaq100 ETF vs Stryker Corporation — how do they compare? Nasdaq100 ETF trades at $751.27 (market cap $506.92B), while Stryker Corporation trades at $277.33 (market cap $106.24B). The key difference: Nasdaq100 ETF is far larger — about 4.8× Stryker Corporation's market cap, and Stryker Corporation pays a 1.27% dividend while Nasdaq100 ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nasdaq100 ETF for 162 Days and Stryker Corporation for 21 Days on average.
| QQQ | SYK | |
|---|---|---|
Market Cap | $506.92B | $106.24B |
Volume | 48,326,518 | 2,982,001 |
52-Week High | $759.66 | $388.35 |
52-Week Low | $558.34 | $269.75 |
Typical Hold Time | 162 Days | 21 Days |
Sector | — | Health |
Enterprise Value | — | $117.70B |
Dividend Yield | — | 1.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QQQ trades at $747.64, down 1.33% on the day, with technical indicators showing a bullish trend supported by moving averages while oscillators remain neutral. The ETF maintains strong institutional interest despite mixed analyst sentiment. Recent news highlights QQQ's concentration in technology stocks and ongoing comparisons with lower-cost alternatives like VOO and QQQM.
The outlook remains positive given QQQ's exposure to leading tech innovators and AI-driven growth potential, though elevated valuations and interest rate sensitivity present near-term risks. Long-term growth prospects appear solid, but investors should monitor concentration risk and fee differentials among competing ETFs.
Stryker (SYK) trades at $276.97, up 0.57% today, amid a bearish technical signal with key support at $274 and resistance at $279. The company reported strong profitability with a 14.43% net income margin and beat Q2 2026 EPS estimates, though it missed in Q1. Recent news highlights ongoing legal scrutiny related to manufacturing issues disclosed in September 2026, which caused a significant share price drop.
Analyst consensus remains strongly bullish with a $368.11 price target, but risks include persistent manufacturing problems and potential securities litigation. Earnings growth and margin expansion support the long-term outlook, though near-term volatility may persist pending Q3 2026 results on October 29, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nasdaq100 ETF
The ETF is designed to track the performance of the securities and the stocks in the NASDAQ-100 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on QQQ →About Stryker Corporation
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →
